Lexaria Bioscience Corp. LEXX shares are trading higher after the company announced its DehydraTECH significantly enhances delivery of colchicine in study VIRAL-A20-3.
This study demonstrated that DehydraTECHTM enabled colchicine, the latest of several drugs Lexaria has successfully tested with known SARS-CoV-2 antiviral properties, said in the company's press release.
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery.
Lexaria's stock was trading about 54% higher at $10.14 per share on Wednesday at the time of publication. The stock has a 52-week high of $12.50 and a 52-week low of $3.97.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
